probucol has been researched along with Coronary Stenosis in 5 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When probucol was administered in a dose of 250 mg/day for 7-10 days before transluminal balloon coronary angioplasty and then for 6 months after surgery, the incidence of restenosis decreased to 25% compared to 45% in the control (without probucol therapy)." | 2.71 | Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty. ( Belenkov, YN; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Perepelitsa, EI; Polevaya, TY; Provatorov, SI; Samko, AN; Sozykin, AL; Tikhaze, AK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, M | 1 |
| Xu, B | 1 |
| Kandzari, DE | 1 |
| Wu, Y | 1 |
| Yan, H | 1 |
| Chen, J | 1 |
| Qian, J | 1 |
| Qiao, S | 1 |
| Yang, Y | 1 |
| Gao, RL | 1 |
| Kaminnyi, AI | 2 |
| Lankin, VZ | 2 |
| Perepelitsa, EI | 2 |
| Konovalova, GG | 2 |
| Samko, AN | 2 |
| Tikhaze, AK | 2 |
| Kukharchuk, VV | 2 |
| Belenkov, YN | 2 |
| Byrne, RA | 1 |
| Mehilli, J | 1 |
| Iijima, R | 1 |
| Schulz, S | 1 |
| Pache, J | 1 |
| Seyfarth, M | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| Wakeyama, T | 1 |
| Ogawa, H | 1 |
| Iida, H | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Mochizuki, M | 1 |
| Tanaka, T | 1 |
| Sozykin, AL | 1 |
| Provatorov, SI | 1 |
| Polevaya, TY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis[NCT00332397] | Phase 4 | 1,007 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for probucol and Coronary Stenosis
| Article | Year |
|---|---|
First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
Topics: Cardiovascular Agents; China; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug Com | 2014 |
Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antioxidants; Combined Modality Therapy; Coronary Angio | 2007 |
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Topics: Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Disease-Free Survival; Drug-Elut | 2009 |
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co | 2003 |
Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Restenosis; Coronary Stenosis; Humans; Male; | 2005 |